GlassScriptPhysician profile
Dongkwan Jin
NPI 1508310111
$4,348.01
in general payments reported to CMS, 2019-2025
33 companies · $81.92 in 2025
The $81.92 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $15.91 · 2021: $111 · 2022: $442 · 2023: $2,556 · 2024: $755 · 2025: $81.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636 · Travel and Lodging: $739 · Education: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,636.11 |
| Travel and Lodging | $738.94 |
| Education | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,027.88 | 2022-2024 | Infinity |
| Abbvie INC. | $451.57 | 2020-2024 | |
| Ucb, INC. | $422.30 | 2023-2025 | Fintepla, Nayzilam, Briviact |
| Lilly USA, LLC | $213.47 | 2021-2024 | Amyvid, Reyvow, Emgality |
| Alexion Pharmaceuticals, INC. | $191.28 | 2023 | Soliris, Ultomiris |
| Mdd US Operations, LLC | $190.10 | 2023-2024 | Gocovri, Gocovri |
| Pfizer INC. | $163.54 | 2023-2024 | |
| Sk Life Science, INC. | $151.10 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $135.99 | 2022-2024 | |
| Emd Serono, INC. | $127.62 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.55 | 2019 | |
| Genzyme Corporation | $117.54 | 2019-2022 | |
| Argenx US, INC. | $102.83 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $79.74 | 2022-2023 | |
| Amgen INC. | $76.36 | 2022-2023 | Aimovig |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $73.96 | 2019-2024 | Ingrezza |
| Genentech USA, INC. | $73.33 | 2022-2023 | Ocrevus, Enspryng |
| Lundbeck LLC | $71.59 | 2022-2024 | Vyepti |
| Cala Health, INC. | $64.42 | 2025 | Cala Kiq |
| Allergan, INC. | $60.38 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.21 | 2022 | |
| Csl Behring | $51.48 | 2024 | Hizentra |
| Amneal Pharmaceuticals LLC | $48.93 | 2023 | Rytary |
| Tanabe Pharma America, INC. | $48.33 | 2023 | |
| Insightec,INC | $46.78 | 2023 | Exablate |
| Kyowa Kirin, INC. | $36.27 | 2023 | Nourianz |
| Biogen, INC. | $36.05 | 2022-2024 | Tysabri, Vumerity |
| Livanova USA, INC. | $21.16 | 2022 | |
| Merz Pharmaceuticals, LLC | $20.36 | 2023 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $16.30 | 2024 | Nuedexta |
| Banner Life Sciences, LLC | $15.69 | 2023 | |
| Acadia Pharmaceuticals INC | $15.64 | 2022 | |
| Acorda Therapeutics, INC | $15.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dongkwan Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.